智通财经APP获悉，长风药业(02652)涨超5%，截至发稿，涨3.34%，报21.64港元，成交额1074.56万港元。
消息面上，4月27日，长风药业宣布，公司在呼吸介入医疗器械治疗领域取得关键性临床进展：其自主研发的支气管内活瓣(EBV)在治疗重度肺气肿的临床试验中，首例患者术后治疗效果良好，已顺利完成临床观察并出组。这一进展标志着公司实现了从吸入药物到介入器械的系统性管线布局。首例患者顺利完成临床试验治疗与出组，是EBV项目研发进程中的重要里程碑，也为后续临床试验的推进积累了宝贵经验。
作为深耕吸入制剂与呼吸系统疾病研发、生产和商业化的综合性创新药企，长风药业已建立起覆盖哮喘、COPD、过敏性鼻炎等多病种的产品矩阵。公司拥有粒子工程、装置设计、产品性能评估、临床开发、工艺工程五大核心技术平台，支撑创新药与器械的同步研发。EBV项目的稳步推进，使公司从吸入药物治疗延伸至介入器械治疗，构建起覆盖轻中度疾病药物干预到重度、重度疾病器械介入的全病程管理方案，进一步强化了在呼吸疾病治疗领域的综合布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.